BioSpace News Archive

While attending the 2023 BIO International Convention, Samsung Biologics, a leading contract development and manufacturing organization, revealed details of the company’s future expansion plan to have its new fifth plant operational by April 2025.

AgBiome®, Inc. and Ginkgo Bioworks announced a partnership to optimize the performance of products in AgBiome’s pipeline of agricultural biologicals.

Candesant Biomedical , Inc. today announced the closing of a Series B financing, raising a total of $35 million to advance the commercialization of Brella, the first-and-only FDA-cleared 3-Minute SweatControl Patch.

BPGbio, Inc today announced that patients have been initially dosed in its Phase 2 trial for BPM 31510 for Glioblastoma Multiforme (GBM), a fast-growing and aggressive form of brain cancer.

Theralase Technologies Inc. is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc.

Intensity Therapeutics, Inc. today announced that data from its INVINCIBLE study was presented on June 4, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and virtually from June 2-6, 2023.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the 2023 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY.

To support stronger healthcare delivery and outcomes in West Africa, Shanghai Fosun Pharmaceutical Co., Ltd. announced a deepening partnership with IFC to help the company build a pharmaceutical production facility and distribution hub in Côte d’Ivoire.

Achieve Life Sciences, Inc. announced that John Bencich, CEO of Achieve, will be presenting at the LD Micro Invitational XIII in Los Angeles and the Maxim Virtual Healthcare Conference.

Elicio Therapeutics (NASDAQ:ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, provides a corporate update on a series of advancements for the company, including the completion of its reverse merger earlier this month in an all-stock transaction.